跳至主要内容
临床试验/KCT0002946
KCT0002946已完成未知

The Prospective, multicenter, double-blinded(Subject-independent evaluator), randomized, and pivotal clinical trial to compare the efficacy and safety of Collabarrier® with Guardix-SOL for the prevention of postoperative adhesion in Intrauterine surgery.

Dalim Tissen0 个研究点目标入组 188 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
188

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 o Limit(—)
性别
Female

入选标准

  • 1. Female at least 19 years old
  • 2. Patients scheduled for intrauterine surgery because of the following gynecological diseases
  • - Submucosal myoma
  • - Endometrial polyp
  • - Uterine septa
  • - Endometrial hyperplasia
  • - Intrauterine adhesion
  • - Abnormal uterine bleeding
  • 3. Patients who are willing to voluntarily participate in the trial and are willing to follow the protocol

排除标准

  • If any of the following criteria are met, a target subject can not be enrolled.
  • ? Pregnant, lactating women, and women having a pregnancy plan during the clinical trial
  • ? Patients who intend to use an intrauterine device for contraception during the clinical trial
  • ? Patients who need hormone therapy after intrauterine surgery
  • ? Patients who had GnRH hormone therapy within 3 months before screening
  • ? Patients who have local or systemic infection, endometrial cancer (uterus and endometrium, cervical cancer) and excessive uterine bleeding
  • ? Patients who have abnormal liver function, abnormal kidney function, abnormal hemostatic function
  • ? Patients who are applied anti-coagulants or who took systemic steroids within 1 week before surgical operation
  • ? Patients with immunosuppression or autoimmune diseases
  • ? Patients with uncontrolled diabetes
  • ? Patients with hypersensitivity to the medical device for clinical trials
  • ? Patients who have participated in other clinical trials within 30 days prior to participating in this clinical trial
  • ? In the case that investigators made a decision that a person is inappropriate to participate in the clinical trial

研究者

发起方
Dalim Tissen

相似试验

进行中(未招募)
不适用
A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Tissugel Heparine in the treatment of ankle sprains. - NDankle sprainsMedDRA version: 9.1Level: LLTClassification code 10023229Term: Joint sprain
EUCTR2006-003773-28-ITIBSA420
进行中(未招募)
不适用
A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Tissugel Héparine in the treatment of mild-to-moderate contusions.mild-to-moderate contusions
EUCTR2005-003829-31-DEIBSA Institut Biochimique S.A.330
进行中(未招募)
1 期
A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Tissugel Héparine in the treatment of mild-to-moderate contusions.Muscle contusion with hematoma and pain of upper or lower limbs
EUCTR2005-003829-31-CZIBSA, Institut Biochimique S.A.330
进行中(未招募)
1 期
Multicentre, prospective, double-blind, in parallel groups, randomized, placebo-controlled clinical trial to evaluate the short-term efficacy and safety of Betamethasone valerate 2.25 mg medicated plaster in patients with chronic lateral epicondylitis (tennis elbow)Chronic Lateral Elbow TendinopathyMedDRA version: 17.1Level: LLTClassification code 10043258Term: Tennis elbowSystem Organ Class: 100000004863MedDRA version: 17.1Level: LLTClassification code 10024032Term: Lateral epicondylitisSystem Organ Class: 100000004863
EUCTR2014-004119-35-ITIBSA Institut Biochimique SA
已完成
不适用
Evaluation of external beam radiation to prevent restenosis after femoropopliteal stentingPeripheral vascular disease/femoropopliteal artery obstructionCirculatory SystemOther peripheral vascular diseases
ISRCTN74370657Hôtel-Dieu de Montréal (Canada)214